Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.

"Declarations Ethical approvalThe studies involving human participants were reviewed and approved by the Ethics Committee of Fifth Medical Center of Chinese PLA General Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) to publish any potentially identifiable images or data in this article. The animal study was reviewed and approved by the Ethics Committee of Fifth Medical Center of Chinese PLA General Hospital (ky-2018-5-37). Written informed consent was obtained from the owners for the participation of their animals in this study. Consent for publicationNot applicable. Competing of interestsAll authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. SAFE Pharmaceutical Research Institute Company employed J. Du and QJ Wang. Competing of interests All authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. SAFE Pharmaceutical Research Institute Company employed J. Du and QJ Wang."

"Funding 1. Hospital project of Strategic Support Force Medical Center (21ZX01). 2. National Natural Science Foundation of China (82100239). 3. Key Discipline Construction Project of PLA Medical Academy[A350109-12]. 4. National Natural Science Foundation of China [31900678]."